Sabra Healthcare REIT (SBRA)
(Delayed Data from NSDQ)
$13.70 USD
-0.08 (-0.58%)
Updated Apr 24, 2024 04:00 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Sabra Healthcare (SBRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$15.46 | $21.00 | $12.50 | 12.85% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Sabra Healthcare comes to $15.46. The forecasts range from a low of $12.50 to a high of $21.00. The average price target represents an increase of 12.85% from the last closing price of $13.70.
Analyst Price Targets (12)
Broker Rating
Sabra Healthcare currently has an average brokerage recommendation (ABR) of 2.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 2.20 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, six are Strong Buy, representing 40% of all recommendations. A month ago, Strong Buy represented 40%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 9 | 9 | 9 | 10 | 10 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.20 | 2.20 | 2.20 | 2.18 | 2.18 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/5/2024 | Truist Securities | Michael Lewis | Strong Buy | Strong Buy |
3/15/2024 | KeyBanc Capital Markets | Austin Wurschmidt | Hold | Hold |
2/29/2024 | Wedbush Securities | Richard Anderson | Strong Buy | Strong Buy |
2/29/2024 | Scotiabank | Nicholas Yulico | Hold | Hold |
1/3/2024 | Mizuho SecuritiesUSA | Vikram Malhotra | Strong Buy | Strong Buy |
12/18/2023 | Not Identified | Not Identified | Hold | Hold |
12/1/2023 | JMP Securities | Aaron Hecht | Hold | Hold |
10/17/2023 | BMO Capital Markets | John P Kim | Not Available | Hold |
8/17/2023 | Robert W. Baird & Co. | Wesley Golladay | Hold | Hold |
7/27/2023 | Berenberg Bank | Tammy Qiu | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.20 |
ABR (Last week) | 2.20 |
# of Recs in ABR | 15 |
Average Target Price | $15.46 |
LT Growth Rate | 2.00% |
Industry | REIT and Equity Trust - Other |
Industry Rank by ABR | 147 of 252 |
Current Quarter EPS Est: | 0.34 |